2016 Board Review Course Clinical Science III

Now that you have completed this activity, please provide feedback regarding its quality and the impact it will have on your practice.

Learning Objectives

Please rate your ability to perform the following objectives upon completion of this activity, with 1 = Not confident and 5 = Able to demonstrate *

	1	2	3	4	5
Learning Objective 1: Discuss a strategy for laboratory testing in patients with recurrent infection utilizing flow cytometry and functional immune testing to clarify the diagnosis and therapeutic options	Learning Objective 1: Discuss a strategy for laboratory testing in patients with recurrent infection utilizing flow cytometry and functional immune testing to clarify the diagnosis and therapeutic options - 1	Learning Objective 1: Discuss a strategy for laboratory testing in patients with recurrent infection utilizing flow cytometry and functional immune testing to clarify the diagnosis and therapeutic options - 2	Learning Objective 1: Discuss a strategy for laboratory testing in patients with recurrent infection utilizing flow cytometry and functional immune testing to clarify the diagnosis and therapeutic options - 3	Learning Objective 1: Discuss a strategy for laboratory testing in patients with recurrent infection utilizing flow cytometry and functional immune testing to clarify the diagnosis and therapeutic options - 4	Learning Objective 1: Discuss a strategy for laboratory testing in patients with recurrent infection utilizing flow cytometry and functional immune testing to clarify the diagnosis and therapeutic options - 5
Learning Objective 2: Discuss the principles of specific IgE testing and the utility of tryptase testing	Learning Objective 2: Discuss the principles of specific IgE testing and the utility of tryptase testing - 1	Learning Objective 2: Discuss the principles of specific IgE testing and the utility of tryptase testing - 2	Learning Objective 2: Discuss the principles of specific IgE testing and the utility of tryptase testing - 3	Learning Objective 2: Discuss the principles of specific IgE testing and the utility of tryptase testing - 4	Learning Objective 2: Discuss the principles of specific IgE testing and the utility of tryptase testing - 5
Learning Objective 3: Identify the rationale and approach including HLA typing, donor selection and use of conditioning for hematopoietic stem cell transplantation for patients with primary immune deficiencies and how these approaches differ for SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease	Learning Objective 3: Identify the rationale and approach including HLA typing, donor selection and use of conditioning for hematopoietic stem cell transplantation for patients with primary immune deficiencies and how these approaches differ for SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease - 1	Learning Objective 3: Identify the rationale and approach including HLA typing, donor selection and use of conditioning for hematopoietic stem cell transplantation for patients with primary immune deficiencies and how these approaches differ for SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease - 2	Learning Objective 3: Identify the rationale and approach including HLA typing, donor selection and use of conditioning for hematopoietic stem cell transplantation for patients with primary immune deficiencies and how these approaches differ for SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease - 3	Learning Objective 3: Identify the rationale and approach including HLA typing, donor selection and use of conditioning for hematopoietic stem cell transplantation for patients with primary immune deficiencies and how these approaches differ for SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease - 4	Learning Objective 3: Identify the rationale and approach including HLA typing, donor selection and use of conditioning for hematopoietic stem cell transplantation for patients with primary immune deficiencies and how these approaches differ for SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease - 5
Learning Objective 4: Discuss the approaches and risks using exogenous gene therapy for patients with primary immune deficiencies including SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease	Learning Objective 4: Discuss the approaches and risks using exogenous gene therapy for patients with primary immune deficiencies including SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease - 1	Learning Objective 4: Discuss the approaches and risks using exogenous gene therapy for patients with primary immune deficiencies including SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease - 2	Learning Objective 4: Discuss the approaches and risks using exogenous gene therapy for patients with primary immune deficiencies including SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease - 3	Learning Objective 4: Discuss the approaches and risks using exogenous gene therapy for patients with primary immune deficiencies including SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease - 4	Learning Objective 4: Discuss the approaches and risks using exogenous gene therapy for patients with primary immune deficiencies including SCID, Wiskott Aldrich Syndrome and Chronic Granulomatous Disease - 5
Learning Objective 5: Describe the biologics that may be useful in patients with atopic asthma	Learning Objective 5: Describe the biologics that may be useful in patients with atopic asthma - 1	Learning Objective 5: Describe the biologics that may be useful in patients with atopic asthma - 2	Learning Objective 5: Describe the biologics that may be useful in patients with atopic asthma - 3	Learning Objective 5: Describe the biologics that may be useful in patients with atopic asthma - 4	Learning Objective 5: Describe the biologics that may be useful in patients with atopic asthma - 5
Learning Objective 6: Describe replacement immunoglobulin therapy in patients with antibody deficiency and identify the possible risk factors that may lead to adverse events of the therapy	Learning Objective 6: Describe replacement immunoglobulin therapy in patients with antibody deficiency and identify the possible risk factors that may lead to adverse events of the therapy - 1	Learning Objective 6: Describe replacement immunoglobulin therapy in patients with antibody deficiency and identify the possible risk factors that may lead to adverse events of the therapy - 2	Learning Objective 6: Describe replacement immunoglobulin therapy in patients with antibody deficiency and identify the possible risk factors that may lead to adverse events of the therapy - 3	Learning Objective 6: Describe replacement immunoglobulin therapy in patients with antibody deficiency and identify the possible risk factors that may lead to adverse events of the therapy - 4	Learning Objective 6: Describe replacement immunoglobulin therapy in patients with antibody deficiency and identify the possible risk factors that may lead to adverse events of the therapy - 5

Thomas A. Fleisher, MD FAAAAI

Laboratory Immunology - Thomas A. Fleisher, MD FAAAAI *

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Disclosed potential conflicts of interest before beginning the activity	Disclosed potential conflicts of interest before beginning the activity - Strongly Disagree	Disclosed potential conflicts of interest before beginning the activity - Disagree	Disclosed potential conflicts of interest before beginning the activity - Neutral	Disclosed potential conflicts of interest before beginning the activity - Agree	Disclosed potential conflicts of interest before beginning the activity - Strongly Agree
Demonstrated appropriate expertise in the subject area	Demonstrated appropriate expertise in the subject area - Strongly Disagree	Demonstrated appropriate expertise in the subject area - Disagree	Demonstrated appropriate expertise in the subject area - Neutral	Demonstrated appropriate expertise in the subject area - Agree	Demonstrated appropriate expertise in the subject area - Strongly Agree
Demonstrated effective presentation skills that engaged the audience	Demonstrated effective presentation skills that engaged the audience - Strongly Disagree	Demonstrated effective presentation skills that engaged the audience - Disagree	Demonstrated effective presentation skills that engaged the audience - Neutral	Demonstrated effective presentation skills that engaged the audience - Agree	Demonstrated effective presentation skills that engaged the audience - Strongly Agree
Provided syllabus materials that enhanced learning from the presentation	Provided syllabus materials that enhanced learning from the presentation - Strongly Disagree	Provided syllabus materials that enhanced learning from the presentation - Disagree	Provided syllabus materials that enhanced learning from the presentation - Neutral	Provided syllabus materials that enhanced learning from the presentation - Agree	Provided syllabus materials that enhanced learning from the presentation - Strongly Agree
Should be invited to present at future courses	Should be invited to present at future courses - Strongly Disagree	Should be invited to present at future courses - Disagree	Should be invited to present at future courses - Neutral	Should be invited to present at future courses - Agree	Should be invited to present at future courses - Strongly Agree
Provided a presentation that prepared you for your upcoming certification/recertification	Provided a presentation that prepared you for your upcoming certification/recertification - Strongly Disagree	Provided a presentation that prepared you for your upcoming certification/recertification - Disagree	Provided a presentation that prepared you for your upcoming certification/recertification - Neutral	Provided a presentation that prepared you for your upcoming certification/recertification - Agree	Provided a presentation that prepared you for your upcoming certification/recertification - Strongly Agree

Morton Cowan, MD

HLA, Stem Cell Transplantation and Gene Therapy - Morton Cowan, MD *

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Disclosed potential conflicts of interest before beginning the activity	Disclosed potential conflicts of interest before beginning the activity - Strongly Disagree	Disclosed potential conflicts of interest before beginning the activity - Disagree	Disclosed potential conflicts of interest before beginning the activity - Neutral	Disclosed potential conflicts of interest before beginning the activity - Agree	Disclosed potential conflicts of interest before beginning the activity - Strongly Agree
Demonstrated appropriate expertise in the subject area	Demonstrated appropriate expertise in the subject area - Strongly Disagree	Demonstrated appropriate expertise in the subject area - Disagree	Demonstrated appropriate expertise in the subject area - Neutral	Demonstrated appropriate expertise in the subject area - Agree	Demonstrated appropriate expertise in the subject area - Strongly Agree
Demonstrated effective presentation skills that engaged the audience	Demonstrated effective presentation skills that engaged the audience - Strongly Disagree	Demonstrated effective presentation skills that engaged the audience - Disagree	Demonstrated effective presentation skills that engaged the audience - Neutral	Demonstrated effective presentation skills that engaged the audience - Agree	Demonstrated effective presentation skills that engaged the audience - Strongly Agree
Provided syllabus materials that enhanced learning from the presentation	Provided syllabus materials that enhanced learning from the presentation - Strongly Disagree	Provided syllabus materials that enhanced learning from the presentation - Disagree	Provided syllabus materials that enhanced learning from the presentation - Neutral	Provided syllabus materials that enhanced learning from the presentation - Agree	Provided syllabus materials that enhanced learning from the presentation - Strongly Agree
Should be invited to present at future courses	Should be invited to present at future courses - Strongly Disagree	Should be invited to present at future courses - Disagree	Should be invited to present at future courses - Neutral	Should be invited to present at future courses - Agree	Should be invited to present at future courses - Strongly Agree
Provided a presentation that prepared you for your upcoming certification/recertification	Provided a presentation that prepared you for your upcoming certification/recertification - Strongly Disagree	Provided a presentation that prepared you for your upcoming certification/recertification - Disagree	Provided a presentation that prepared you for your upcoming certification/recertification - Neutral	Provided a presentation that prepared you for your upcoming certification/recertification - Agree	Provided a presentation that prepared you for your upcoming certification/recertification - Strongly Agree

Mark Ballow, MD FAAAAI

IV/SC Ig and Biological Modifiers - Mark Ballow, MD FAAAAI *

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Disclosed potential conflicts of interest before beginning the activity	Disclosed potential conflicts of interest before beginning the activity - Strongly Disagree	Disclosed potential conflicts of interest before beginning the activity - Disagree	Disclosed potential conflicts of interest before beginning the activity - Neutral	Disclosed potential conflicts of interest before beginning the activity - Agree	Disclosed potential conflicts of interest before beginning the activity - Strongly Agree
Demonstrated appropriate expertise in the subject area	Demonstrated appropriate expertise in the subject area - Strongly Disagree	Demonstrated appropriate expertise in the subject area - Disagree	Demonstrated appropriate expertise in the subject area - Neutral	Demonstrated appropriate expertise in the subject area - Agree	Demonstrated appropriate expertise in the subject area - Strongly Agree
Demonstrated effective presentation skills that engaged the audience	Demonstrated effective presentation skills that engaged the audience - Strongly Disagree	Demonstrated effective presentation skills that engaged the audience - Disagree	Demonstrated effective presentation skills that engaged the audience - Neutral	Demonstrated effective presentation skills that engaged the audience - Agree	Demonstrated effective presentation skills that engaged the audience - Strongly Agree
Provided syllabus materials that enhanced learning from the presentation	Provided syllabus materials that enhanced learning from the presentation - Strongly Disagree	Provided syllabus materials that enhanced learning from the presentation - Disagree	Provided syllabus materials that enhanced learning from the presentation - Neutral	Provided syllabus materials that enhanced learning from the presentation - Agree	Provided syllabus materials that enhanced learning from the presentation - Strongly Agree
Should be invited to present at future courses	Should be invited to present at future courses - Strongly Disagree	Should be invited to present at future courses - Disagree	Should be invited to present at future courses - Neutral	Should be invited to present at future courses - Agree	Should be invited to present at future courses - Strongly Agree
Provided a presentation that prepared you for your upcoming certification/recertification	Provided a presentation that prepared you for your upcoming certification/recertification - Strongly Disagree	Provided a presentation that prepared you for your upcoming certification/recertification - Disagree	Provided a presentation that prepared you for your upcoming certification/recertification - Neutral	Provided a presentation that prepared you for your upcoming certification/recertification - Agree	Provided a presentation that prepared you for your upcoming certification/recertification - Strongly Agree

Commerical Bias

Did you detect any commercial bias in this activity? *

Yes

No Answer

If you detected bias, please describe the biased content:

Change in Practice

Based on knowledge and skills you gained in completing this activity, do you plan to make changes to your practice (patient care, research, or teaching)? *

Yes

No Answer

If you plan to change your practice based on what you have learned, please describe below:

If you have not made or do not plan to make changes to your practice based on what you learned by completing this activity, please indicate why. Select all that apply:

Need to learn more before I feel comfortable changing my practice

Knowledge and skills I gained did not have an immediate application

Knowledge and skills I gained reinforced my current practice behaviors

Financial limitations

Staffing limitations

Other:

If you have not made or do not plan to make changes to your practice based on what you learned by completing this activity, please indicate why. Select all that apply: Other:

Additional Comments

After attending this activity, what do you need to learn more about to improve your practice (patient care, research, or teaching)?

Please provide any additional comments you would like to share:

Leave this field blank

AAAAI Education Center

Add to favorites link

2016 Board Review Course Clinical Science III

You are here

2016 Board Review Course Clinical Science III